Journal of Clinical Oncology
Articles in this Issue
Phase II study of olaparib plus ATR inhibitor ceralasertib in patients with metastatic breast cancer and germline BRCA1/2 pathogenic variants who progressed on prior PARP inhibitor therapy.
1142 Background: PARP inhibitors (PARPi) olparib and talazoparib improve objective response rate (ORR) and disease-free su...
Novel adaptive versus continuous dosing of encorafenib and binimetinib in combination with nivolumab in advanced <i>BRAF V600E</i> mutant melanoma.
9538 Background: In BRAF V600 mutant melanoma, continuous treatment with BRAF/MEK inhibitors invariably begets acquired re...
Impact of pembrolizumab infusion timing on outcomes in early-stage triple-negative breast cancer: A real-world exploratory analysis (Neo-Real).
610 Background: Neoadjuvant pembrolizumab combined with chemotherapy is the standard of care for early-stage triple-negati...
Liver transplantation as a therapeutic strategy for far-advanced hepatic malignancies: Survival outcomes from the LT-FAM study.
e16238 Background: As liver transplantation (LT) indications expand, it is increasingly explored for select patients with...
Pan-cancer discovery of clinical and genomic determinants of immune-related adverse events.
11132 Background: Immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) can be lifelong, fatal, o...
Linking T-cell receptor dynamics to outcomes in neoadjuvant-treated melanoma.
9573 Background: Clinical Stage III (cSIII) melanoma patients are at high risk of recurrence following therapeutic lymph n...
Phase II pilot study of pembrolizumab (PEM) and neoadjuvant radiation therapy (nRT) in high-risk soft tissue sarcomas (STS).
11584 Background: Pathologic necrosis (PN) after neoadjuvant therapy in STS has been associated with improved outcomes. We...
Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402.
8079 Background: Lurbi received accelerated approval in 2020 for ES-SCLC that progressed on or after platinum-based treatm...
A deep learning approach to quantitatively capture cerebellar overgrowth in pediatric NF1 patients.
e14001 Background: Macrocephaly is one of the most common clinical manifestations of NF1 patients. As compared to normals,...
Development of an AI-based transcriptional surrogate for epigenetic aging in breast cancer.
e12575 Background: In our previous omics studies of breast cancer in Mexican patients, we observed an unexpected enrichmen...
Efficacy and safety analysis of T-DXd versus anti-TROP2 ADCs therapy in HER2-low advanced breast cancer.
e15046 Background: Trastuzumab deruxtecan (T-DXd) and anti-Trophoblast cell-surface antigen(TROP)2 antibody–drug conjugate...
DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM).
7503 Background: DREAMM-9 (NCT04091126) was a phase 1 dose and schedule evaluation study of BVRd in adults with TI NDMM....
Spatial remodeling of the tumor-immune microenvironment (TIME) on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with hormone receptor positive (HR+) early breast cancer (eBC) by multiplex immunofluorescence (mIF).
e12645 Background: NCIT efficacy remains limited in HR+ eBC. Given the role of cell interactions in antitumor immunity, we...
Beyond cardiotoxicity: The hidden burden of functional disability in cardio-oncology survivorship.
e24014 Background: Cardio-oncology traditionally focuses on cardiotoxicity prevention and acute cardiovascular-events. How...
Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma.
11525 Background: Osteosarcoma is a highly malignant and aggressive tumor, predominantly occurring in children and adolesc...
Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal squamous cell carcinoma: A phase II study.
4067 Background: The clinical therapeutic effect for patients with postoperative loco-regional recurrent esophageal squamo...
Predictors of long-term survival in esophageal carcinoma: Is it the same for all stages?
e16152 Background: Survival outcomes in esophageal carcinoma depend on evolving prognostic factors across clinical stages....
AI-enabled multimodal adjudication of revised IMWG progression after BCMA CAR-T.
7521 Background: Real-world ascertainment of clinically meaningful relapse after BCMA CAR-T is challenging because progres...
Impact of <i>STK11</i> / <i>KEAP1</i> / <i>SMARCA4</i> co-mutations in RAS-activated <i>KRAS</i> wild-type metastatic NSCLC treated with immune checkpoint inhibitors.
8565 Background: RAS-activated KRAS wild-type (RASa/KRASwt) non-small cell lung ca...
Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: A national real-world data analysis.
1660 Background: Chronologic age and traditional clinical-pathologic prostate cancer (PCa) risk factors (e.g. PSA, Gleason...
Predictive role of gut microbiota and their metabolites in the efficacy of immune checkpoint inhibitor therapy for lung squamous cell carcinoma.
e20017 Background: Lung squamous cell carcinoma (LUSC) is the second most common subtype of lung cancer. Due to its low dr...
Comparison of DNA+RNA co-detection and DNA-only NGS for driver gene identification and co-mutation profiling in Chinese patients with non–small cell lung cancer.
e20750 Background: Comprehensive identification of oncogenic drivers is essential for precision treatment of NSCLC. Althou...
Molecular and immune profiling of <i>BRAF</i> -mutated ( <i>BRAF</i> <sup>MUT</sup> ) non-small cell lung cancer (NSCLC).
8653 Background: BRAF MUT occur in 6-7% of NSCLC and comprise of biologically dist...
Effects of vancomycin on the gut microbiota and metabolic profile to sensitize microsatellite-stable colorectal cancer to anti-PD-1 immunotherapy.
e15580 Background: Microsatellite-stable (MSS) colorectal cancer (CRC) remains largely refractory to immune checkpoint blo...
Comparative effectiveness of advanced radiofrequency ablation electrode systems for hepatocellular carcinoma: A systematic review and network meta-analysis.
e16237 Background: Percutaneous radiofrequency ablation (RFA) offers a curative option for early-stage hepatocellular carc...